Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (July 2026)
28 slides from Maat Pharma's investor presentation, July 2026
Slide 1: Boosting Survival Through Innovative Immune Modulation
Boosting Survival Through Innovative Immune Modulation July 2026
Slide 2: Disclaimer
MaaT Pharma July 2026 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward -looking statements . These and is for information and background purposes only . independent ve
Slide 3: Company Overview
Company Overview
Slide 4: Xervyteg (MaaT013) in aGvHD: Achieved All Endpoints of ARES Study
MaaT Pharma July 2026 4 Xervyteg ®(MaaT013) in aGvHD : Achieved All Endpoints of ARES Study A Potential First Regulatory Proof of Concept for Microbiome Therapies in Oncology Leadership in Multi -Assets Platform Financial Overview Hemato -Oncology Focused on Oncology Final results of pivotal ARES tr
Slide 5: Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes
MaaT Pharma July 2026 5 Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings Expected benefits Xervyteg ® ( MaaT013) Resolution Control of inflammation and restoration of gut of aGvHD integrity and production of functional metabolites Restorati
Slide 6: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma July 2026 6 Oncology -Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Co -cultured Ecosystem Integrated Production Driving near -term value Progressing next -generation donor - Leading capabilities in full ecosystem with the donor -derived MET -N platform ind
Slide 7: A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset
MaaT Pharma July 2026 7 A Strong Pipeline With Multiple Value Inflection Milestones and a Close -to-Market Asset Recent or Upcoming Indication Program Indication Market potential PRCL Ph. 1 Ph. 2 Ph. 3 MAA Status milestones Positive EU MAA under re - Final Results examination process ARES (Pivotal)
Slide 8: Xervyteg (MaaT013) in aGvHD
Xervyteg ® (MaaT013) in aGvHD
Slide 9: 3L aGvHD: ~70% 1-yr mortality, no approved therapies
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaT Pharma EMA/FDA Quick action → Quick → action July 2026 9 3L aGvHD : ~70% 1-yr mortality, no approved therapies, ~3k EU/US pts/yr Donor immune cells recognize the recipient’s tissues as Treatment Paradigm in aGvHD foreign , leading to an imm
Slide 10: ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day-28 GI-ORR
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action July 2026 10 ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day -28 GI -ORR; Responses Sustained Through Month 3 Final Results D28 Response Rate (%)* (n=66) “ These results indicate that MaaT013 offers a durable • Day 56
Slide 11: ARES: Higher Observed Overall Survival vs Best Available Therapy in Third-Line
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action July 2026 11 ARES: Higher Observed Overall Survival vs Best Available Therapy (BAT) in Third -Line CHRONOS: real world outcomes in CS - and ARES: pivotal study outcomes in CS - and ruxolitinib -refractory GI -aGvHD (n=59) ruxolitini
Slide 12: ARES: a Completed Pivotal Trial Exploring Xervyteg in 3L aGvHD
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaT Pharma EMA/FDA → Quick action → Quick action July 2026 12 ARES: a Completed Pivotal Trial Exploring Xervyteg ®(MaaT013) in 3L aGvHD Treatment Period D1, 5, 10 Primary follow -up Long -term follow -up Pretreatment EOT Screening Vancomycin &
Slide 13: MaaT013 Currently in EMA Re-examination Process Leading a Potential Conditional Marketing Approval
MaaT Pharma July 2026 13 MaaT013( Xervyteg ®) Currently in EMA Re -examination Process Leading a Potential Conditional Marketing Approval The CHMP acknowledges… • High unmet need for 3L aGvHD • Signal of activity but inability to interpret attribution of effect due to single arm design • No quality
Slide 14: Early Access Program Shows an Increasing International Demand from Physicians
MaaT Pharma July 2026 14 Early Access Program Shows an Increasing International Demand from Physicians Number of authorizations Clinical Outcomes (Real World Evidences) 140 +24% 134 • 173 GvHD patients analyzed as of October 2024 and 120 109 presented at EHA 2025 : 100 +75% • Efficacy (All lines) =
Slide 15: MaaT033 in allo-HSCT
MaaT033 in allo-HSCT ee @e @ @ee8e98e#8e#es#se28ess #®
Slide 16: Phoebus (MaaT033) - Phase 2b Randomized Placebo-Controlled Study in Allo-HSCT
MaaT033 • Allo -HSCT → Ambulatory ODD EMA MaaT Pharma → Adjunctive July 2026 16 Phoebus (MaaT033) - Phase 2b, Randomized (1:1), Double -Blinded, Placebo -Controlled Study in Allo -HSCT Visit 1 Visit 2 15 – 21 days Visit 3 Visit 6 Visit 10 D -21 D -7 D -0 Neutrophil recovery D+21 M+3 M+12 Pre Allo -H
Slide 17: Commercial and Distribution Strategy in Hemato-Oncology
Commercial And Distribution Strategy in Hemato - Oncology
Slide 18: Leadership in Hemato-Oncology Across the Full Care Continuum of HSCT
MaaT Pharma July 2026 18 Leadership in Hemato -Oncology Across the Full Care Continuum of HSCT Unique Value Proposition A US/ EU Significant Market Opportunity Unique immunosuppressant -sparing, microbiome -based Xervyteg® (MaaT013) MaaT033 treatment option in aGvHD ~250M € 1 ~500M € 1 Well defined
Slide 19: Licensing Late-Stage Asset Xervyteg to Clinigen for Commercialization in Europe
MaaT Pharma July 2026 19 Licensing Late -Stage Asset Xervyteg ® (MaaT013) to Clinigen for Commercialization in Europe* • Leading position in hospital distribution • Recognized expertise in critical care ~75 -100M € • Hemato -Oncology Portfolio in Europe • Extended network of prescribers • Specialist
Slide 20: Bringing Xervyteg to Market: Financial Terms of the Commercial Partnership for Europe
MaaT Pharma July 2026 20 Bringing Xervyteg ® (MaaT013) to Market: Financial terms of the Commercial Partnership for Europe Financial Terms Upfront payment MAA milestone Sales milestones Royalties on net sales Drug Supply 10.5M€ 12M€ 6M € Mid -thirties Set C ost Terms European Market for Xervyteg ® (
Slide 21: Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
→ cGMP → Scalable MaaT Pharma Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies TM Xervyteg ® (MaaT013) 11,000 3,500 Leading microbiome therapies fully integrated manufacturing and development platform: streamlined MaaT033 1,300,000 6,000 product development, scaleup an
Slide 22: Future Growth Drivers in Immuno-Oncology
Future Growth Drivers in Immuno - Oncology
Slide 23: ICI Primary Resistance, an Unmet Need for Patient with Advanced Cancers
→ ICI MaaT034 MaaT034 ••IOIO–-Solid Melanoma Tumors MaaT Pharma → Combo July 2026 23 ICI Primary Resistance, an Unmet Need for Patient with Advanced Cancers High Unmet Medical Need Around 19 million people diagnosed with cancer 01 each year globally Lung Cancer (NSCLC) 50% (no response) Immune Check
Slide 24: From Proof to Platform: An Integrated IO Approach
MaaT Pharma July 2026 24 From Proof to Platform: An Integrated IO Approach 2 MET -N MET -C IST POC exploratory studies to help inform MET -C platform will lead the Company’s IO strategy clinical development of the MET -C candidates IND enabling Xervyteg ® (MaaT013) - Phase 2a Randomized, Multicenter
Slide 25: Looking Ahead & Key Takeaways
Looking Ahead & Key Takeaways
Slide 26: Several Major Near-Term Value Inflection Expected Milestones
MaaT Pharma July 2026 26 Several Major Near -Term Value Inflection Expected Milestones 2025 2026 2027 2028 Partnered ® (MaaT013) I Xervyteg ® (MaaT013) I GvHD Xervyteg GvHD Xervyteg® (MaaT013) Ares Pivotal D28 GI -ORR results GvHD | MA Under Reexamination GvHD | Potential Pivotal trial * in Jan 25 P
Slide 27: Corporate Social Responsibility
MaaT Pharma July 2026 27 Corporate Social Responsibility MaaT Pharma is a leading, late -stage clinical Patients are the priority. MaaT Pharma is committed → Innovate and raise awareness to deliver Company committed to advancing gut to patients and to the protection of human health by better care, m
Slide 28: Thank you
Thank you